---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-111940"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:39:44.554280+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics reports Q3 net loss $2.0M; APOLLO study shows 66% ORR, 50% CR in NHL

## Summary
- Cash $17.6M + restricted $1.4M; runway into Q3 2026; raised ~$10M via ATM.
- Net loss $2.0M (improved from $2.3M YoY); R&D $2.3M (down from $3.5M).
- APOLLO study: 66% ORR, 50% CR in 12 relapsed NHL patients; durable responses (≥6 months in 5); dose expansion ongoing.
- First patient dosed in OTS RAPID study (MT-401) for AML/MDS; cGMP manufacturing pact with Cellipont.
- Appointed Kathryn Penkus Corzo to Board; two ASH presentations scheduled Dec 2025.

## SEC filing metadata
- accession: 0001104659-25-111940
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465925111940/0001104659-25-111940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465925111940/tm2530894d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-111940
- JSON: https://secwatch.observer/filing/0001104659-25-111940.json
- Plain text: https://secwatch.observer/filing/0001104659-25-111940.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.